Dermata Therapeutics, Inc. 8-K

What Happened

• Dermata Therapeutics, Inc. announced and furnished a press release on March 26, 2026 (Item 2.02) reporting its results of operations for the fiscal year ended December 31, 2025. The company filed the press release as Exhibit 99.1 to the Form 8-K. The filing also includes the Interactive XBRL cover page for the submission.

Key Details

• Filing date: March 26, 2026 (Form 8-K accession 0001493152-26-012991).
• Event type: Item 2.02 — Results of Operations and Financial Condition (press release furnished).
• Reporting period: Fiscal year ended December 31, 2025.
• Exhibit: 99.1 — press release titled “Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025” (financial details are contained in that exhibit).

Why It Matters

• This 8-K signals the company has publicly disclosed its full-year 2025 operating and financial results; those figures (earnings, revenue, cash position, and related commentary) are in the attached press release and are material for investors assessing Dermata’s performance.
• The filing does not report any executive changes, mergers, or other corporate actions—only the furnished financial-results press release—so investors should review Exhibit 99.1 and any subsequent filings for specific revenue, net income/loss, guidance, or liquidity details.